Memo Therapeutics
Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.
About Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Company Facts
- Headquarters
- Schlieren
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- late_stage_venture
- Total Funding
- $108,755,495
- Last Funding Type
- series_c
- Last Funding Date
- 2024-05-07
- Website
- memo-therapeutics.com
Industries & Categories
Biotechnology, Collaboration, Health Care, Medical
Social Links
Canonical: https://fsome.com/organization/memo-therapeutics-93035 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.